


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and Ia below for treating, by virtue of their cytotoxic properties, cancerous tumors and their metastases:



Formula I



Formula Ia

in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and

groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and $n = 1$ to 3 ,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,


- R_5 , R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6) alkoxy (C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy (C_1-C_4) alkyl, $-CHO$, $-COOH$, $-CN$, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, $-phenyl-CO-CH_3$ and $-CH_2-CH_2-N(CH_3)_2$ groups,

$-phenyl-CO-CH_3$ or $-phenyl-CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,


~~and with the exclusion of the compound formula Ia containing the combination $X = O$ and $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$~~

and the addition salts of these compounds with pharmaceutically acceptable acids.

2. (currently amended) A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, and -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₅, R₆ and R₇ are chosen from:
 - hydrogen or a halogen atom,
 - C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ groups in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
morpholino, nitro or SO₃H groups,
groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

and ~~wherein~~ the addition salts of these compounds ~~present are~~ with pharmaceutically acceptable acids ~~in said pharmaceutical composition.~~

3. (previously presented) The pharmaceutical composition as claimed in claim 2, comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens and nitro and amino groups,
- R₅, R₆ and R₇ represent a hydrogen,

and the addition salts of these compounds with pharmaceutically acceptable acids.

4. (currently amended) The pharmaceutical composition as claimed in claim 1, comprising an effective amount of a compound chosen from the compounds of formulae I and Ia in which:

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and groups CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ and n = 1 to 3,
- R₄ is chosen from hydrogen, halogens, and nitro and amino groups,
- R₅ is chosen from a hydrogen, a halogen and a methoxy group,
- R₆ and R₇ are chosen from hydrogen and C₁-C₆ alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl and -CH₂OCOCH₃ groups,

~~with the exclusion of the compound of formula Ia in which R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H,~~

and the addition salts of these compounds with pharmaceutically acceptable acids.

5. (previously presented) The composition as claimed in claim 4, in which the compounds are chosen from:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically
acceptable acids.

6. (cancelled)

7. (previously presented) The process according to
claim 12, wherein said compound is selected from the group
consisting of:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-
one,

5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-
one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-
[1,10]phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-
[1,10]phenanthrolin-9-one,


5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-
phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-
one,


5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically acceptable acids.

8. (currently amended) Compounds of general formulae I and Ia



Formula I



Formula Ia

in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN , $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and $n = 1$ to 3 ,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,


- R_5 , R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6) alkoxy (C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy (C_1-C_4) alkyl, $-CHO$, $-COOH$, $-CN$, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, $-phenyl-CO-CH_3$ and $-CH_2-CH_2-N(CH_3)_2$ groups,

$-phenyl-CO-CH_3$ or $-phenyl-CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

~~with the exclusion of the compounds of formula I in which X = O,~~

~~and, or R₁, R₂, R₄, R₅, R₆, R₇ = H and R₃ = OCH₃,~~

~~and with the exclusion of the compound formula Ia in~~


~~which X = O and R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H,~~

and the addition salts of these compounds with pharmaceutically acceptable acids.

9. (currently amended) Compounds as claimed in claim 8, of formula I in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, and -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₅, R₆ and R₇ are chosen from:
hydrogen or a halogen atom,

C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl and -CH₂-CH₂-N(CH₃)₂ groups, -phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups, groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

~~with the exclusion of the compounds in which X = O,~~
and the addition salts thereof with pharmaceutically acceptable acids.

10. (previously presented) Compounds as claimed in claim 8, which are:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9*H*-quino[4,3,2-*de*][1,10]-phenanthrolin-9-one,
5-bis(2-chloroethyl)amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-(2-chloroethyl)amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
4-bromo-5-amino-9-*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-bromo-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one,
5-amino-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one,
5-bis(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one,
5-(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one,
4-bromo-5-amino-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically acceptable acids.

11. (previously presented) A process for preparing a compound of formula Ia, in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen,

independently of each other, from hydrogen and (C₁-C₄) alkyl groups,


- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,

- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:
 - hydrogen or a halogen atom,
 - C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,


- phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
- morpholino, nitro or SO₃H groups,

groups:




R_{16} and R_{17} being chosen from C_1 - C_6 alkyl groups and Ar being a C_6 - C_{14} aryl group,
which consists in:


a - condensing a chlorobenzoic acid of formula:




with a dimethoxyaniline of formula:




to give a compound of formula IIa:




b - cyclizing the compound of formula IIa to give a compound of formula:




c - converting the compound into a quinone of formula IIIa:



d - reacting the quinone of formula IIIa with an azadiene of formula:



to give a compound of formula IVa:




e - reacting the compound of the formula IVa with dimethylformamide diethyl acetal to give the compound of formula Ia,

f - and, optionally, converting the compound thus obtained into another compound of formula Ia.

12. (previously presented) A process for inhibiting a tumor in a patient comprising administering an effective amount of a compound as defined in claim 1 to said patient.

13. (previously presented) A process for preparing compounds of general formula I, of formula:



in which:

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN , $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ groups and $-N(CH_3)_2$ and $n = 1$ to 3 ,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5 , R_6 and R_7 are chosen from:


hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy,

(C_1-C_6) alkoxy (C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy (C_1-C_4) alkyl,


-CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
morpholino, nitro or SO₃H groups,
groups:




R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,
with the exclusion of the compounds of formula I in which R₁, R₂, R₄, R₅, R₆, R₇ = H and R₃ = OCH₃, which consists


a) in reacting a hydroquinone of formula




with a compound of formula




in the presence of CeCl_3 , $7\text{H}_2\text{O}$ and ethanol to give a compound of formula II



b) in converting the compound of formula II into a compound of formula III in the presence of H_2SO_4 in reflux acetic acid,




c) in reacting the compound of the formula III with $\text{HC}(\text{OC}_2\text{H}_5)_2\text{N}(\text{CH}_3)_2$ in DMF at 120°C to form a compound of formula IV



d) in cyclizing the compound of formula IV to a compound of formula I in the presence of NH_4Cl and AcOH ,

e) optionally converting the compound of formula I thus obtained into another compound of formula II.

14. (currently amended) A compound of formula



in which:


- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-\text{NR}_8\text{R}_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and $(\text{C}_1\text{-C}_4)$ alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,

- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:
hydrogen or a halogen atom,
C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,
-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
morpholino, nitro or SO₃H groups,
groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

with the exclusion of compounds in which ~~either R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H, or R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br, or R₁, R₂, R₄, R₅, R₆, R₇ = H and R₃ = OCH₃, or R₁, R₂, R₃, R₄, R₆, R₇ = H and R₅ = OH or OCH₃ or R₁ = NO₂ and R₂, R₃, R₄, R₅, R₆, R₇ = H,~~

and the addition salts of these compounds with pharmaceutically acceptable acids.